Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders

Cannabis use disorder (CUD) is the most common illicit substance dependence and people with
CUD are highly vulnerable to anxiety disorders. The co-occurrence of anxiety disorders among
those with CUD is a pressing public health matter given elevated anxiety is related to
poorer cannabis treatment outcomes. Cannabis-related problems among those with anxiety
disorders may be maintained by a reliance on cannabis to manage anxiety. Investigations of
the treatment of these conditions when they co-occur have been virtually absent. Motivation
enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT) is an efficacious
intervention for cannabis CUD, yet outcomes are highly limited for anxious patients.
Transdiagnostic anxiety treatments can facilitate the treatment of patients with anxiety
psychopathology regardless of the specific type of anxiety disorder. One such treatment,
False Safety Behavior Elimination Treatment (FSET), may be particularly useful with anxious
patients with CUD as it focuses on the elimination of behaviors that may be effective in
decreasing anxiety in the short-term, but can maintain and even exacerbate anxiety in the
long-term (i.e., false safety behaviors). The use of cannabis to manage anxiety can,
therefore, be targeted in such a treatment. This project tests the feasibility and utility
of a novel, integrated approach to treatment of patients with CUD and anxiety disorders.
Phase I of the project includes development and refinement of a specialized group protocol
(i.e., Integrated Cannabis and Anxiety Reduction Treatment or ICART) for integrating MET-CBT
for CUD with FSET. The initial protocol will be modified based on the experience gained
during group treatment with the integrated treatment. Phase II will be a randomized
controlled trial examining the relative efficacy of the refined ICART treatment versus
MET-CBT alone. After post-treatment assessments, the ICART group will be followed for 3
months to examine maintenance of gains; the participants originally assigned to the control
condition will be offered ICART. It is hypothesized that ICART will produce better outcomes
than the control.

Inclusion Criteria:

1. Diagnosis of cannabis use disorder

2. An additional diagnosis of an anxiety disorder

3. Patient reports that at least some of his/her cannabis use is aimed at reducing
anxiety and/or for social facilitation.

4. Patient reports that cannabis is his/her substance of choice for anxiety management.

5. Concurrent use of psychotropic medications (e.g., selective serotonin reuptake
inhibitors) is permitted as long as patients have been on a stable dose for at least
three months prior to entering the study and they are willing to remain stable on
their medication for the duration of treatment.

6. Age between 18 and 65 years.

7. English language fluency.

8. Willing and able to provide written informed consent.

Exclusion Criteria:

1. Alcohol or illicit substance (non-cannabis) dependence.

2. Cannabis use behavior sufficiently uncontrolled that proper participation in study
protocol would likely be disrupted.

3. History of schizophrenia, bipolar disorder, or organic brain syndrome.

4. Prominent suicidal ideation with intent that is judged to be clinically significant.

5. Mental retardation or another pervasive developmental disability (e.g., Asperger's
Disorder).

6. Sufficiently socially unstable as to preclude completion of study requirements (e.g.,
homeless).

7. Prior simultaneous cognitive behavioral treatment for cannabis dependence and anxiety
disorders.

8. Legally mandated to receive substance abuse treatment.

9. Report of current participation in or intent to participate in an additional (i.e.,
treatments other than MET-CBT or MET alone) anxiety or substance abuse treatment
method during the course of the study.

10. Unwilling to maintain stable dose of regularly-dosed medications during the study

11. Unwilling to cease PRN (pro re nata or "as needed") use of benzodiazepines or other
fast-acting anxiolytics prior to entrance into social situations.